A61K 2039/523
Expressing foreign proteins
Official title: {expressing foreign proteins}
A61K2039/523 (Expressing foreign proteins) appears on 758 US grants and 1,113 published applications in this corpus.
Search patents in A61K- Granted patents
- 758
- Published applications
- 1,113
- Assignees
- 515
- Inventors
- 1,616
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 4 | 0 |
| 1995 | 4 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 4 | 0 |
| 1999 | 9 | 0 |
| 2000 | 6 | 0 |
| 2001 | 8 | 2 |
| 2002 | 9 | 13 |
| 2003 | 8 | 38 |
| 2004 | 7 | 36 |
| 2005 | 17 | 51 |
| 2006 | 23 | 38 |
| 2007 | 13 | 36 |
| 2008 | 21 | 33 |
| 2009 | 28 | 66 |
| 2010 | 39 | 49 |
| 2011 | 25 | 52 |
| 2012 | 37 | 50 |
| 2013 | 27 | 53 |
| 2014 | 35 | 44 |
| 2015 | 39 | 62 |
| 2016 | 52 | 65 |
| 2017 | 38 | 48 |
| 2018 | 60 | 51 |
| 2019 | 37 | 51 |
| 2020 | 50 | 54 |
| 2021 | 36 | 43 |
| 2022 | 27 | 34 |
| 2023 | 25 | 47 |
| 2024 | 24 | 49 |
| 2025 | 20 | 29 |
| 2026 | 17 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for preventing and treating virus infection15 Sep 2026US 12,734,234 B2University of Virginia Patent Foundation
- Tumor immunotherapy composition based on antigen-presenting cells activated by attenuated listeria monocytogenes, preparation method therefor and application thereof11 Aug 2026US 12,702,681 B2Shanghai RoyalTech Med CO., Ltd
- Method of producing an immunogenic composition7 Jul 2026US 12,673,094 B2Boehringer Ingelheim Animal Health USA Inc.
- Coronavirus vaccine based on controllable secretory expression of attenuated salmonella, preparation method therefor, and application thereof7 Jul 2026US 12,673,099 B2Jiangsu Target Biomedical Research Institute Co., Ltd.
- Use of BCG immunogenic formulation expressing a respiratory syncitial virus protein against hMPV30 Jun 2026US 12,667,611 B2Pontificia Universidad Catolica De Chile
- Orally-delivered vaccines for domesticated and wild animals to prevent pathogen spread using recombinant probiotic bacteria1 Oct 2026US 2026/0295027 A1
- Oral vaccine20 Aug 2026US 2026/0240985 A1WestfäLische Wilhelms-UniversitäT MüNster
- Vaccines against clostridioides difficile and methods of using the same13 Aug 2026US 2026/0232785 A1
- Tumor-targeting pharmaceutical combinations30 Jul 2026US 2026/0216257 A1Baccine Ltd.
- Method of producing an immunogenic composition30 Jul 2026US 2026/0216312 A1Boehringer Ingelheim Animal Health USA Inc.
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant395US 6,406,705 B1Coley Pharmaceutical GmbH · 2002
- Recombinant new castle disease virus RNA expression systems and vaccines164US 6,146,642 AMount Sinai School of Medicine of the City University of New York · 2000
- System and method for measuring animals128US 8,036,429 B22011
- Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response111US 5,830,702 AThe Trustees of the University of Pennsylvania · 1998